RxDoctor Payments Data

Cynthia Rudert, MD

Gastroenterology · Atlanta, GANPI 1225116155

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $614,494 of the $720,354 with a category attached, or 85.3%. AbbVie accounts for 65.8% of it on its own, with 13 other manufacturers making up the rest. Among gastroenterology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$720,354in general payments, 2019–2025

Across 776 payments — averaging $928.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$474K
  • Nestle Healthcare Nutrition Inc.$200K
  • Vivus LLC$25K
  • Aimmune Therapeutics, Inc.$19K
  • Digestive Care, Inc.$733
  • QOL Medical, LLC$212
  • plus $535 from 8 others

What the payments were for

  • Consulting fees$7,6001%
  • Speaking & faculty fees$614,49485%
  • Travel & lodging$87,16312%
  • Food & beverage$11,0972%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)534$474,339
Nestle Healthcare Nutrition Inc.150$199,716
Vivus LLC42$25,319
Aimmune Therapeutics, Inc.14$19,499
Digestive Care, Inc.4$733
QOL Medical, LLC9$212
Alfasigma USA, Inc.7$173
Pfizer1$97
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$83
Concordia Pharmaceuticals Inc.6$78
Exact Sciences2$43
Ferring Pharmaceuticals Inc.1$25
Phathom Pharmaceuticals, Inc.1$25
Endo Pharmaceuticals Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$720,354 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$49,986
Medicare patients
137
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase97$525,869
ZenpepLipase/Protease/Amylase19$298,001
Sucralfate12$1,223
Clotrimazole12$1,190
Fluconazole25$463
Nystatin15$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$474,339$525,86997 claims
Aimmune Therapeutics, Inc.Zenpep$19,499$298,00119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →